Clinical Trial Intelligence

Analyze the clinical trial landscape for [therapeutic target or disease area]:

Focus:
- Target/pathway: [e.g., STAT6, IRAK4, PD-1, KRAS G12C]
- Modality: [small molecule, biologic, degrader, gene therapy, etc.]
- Geography: [global, US, EU, specific region]

Provide:
1. Active trial inventory — list all recruiting and active trials with NCT IDs, sponsors, phase, enrollment, and primary endpoints
2. Phase distribution — how many trials at each phase (1, 1/2, 2, 3, approved)
3. Sponsor analysis — who are the most active sponsors and what is their strategy
4. Design trends — are trials randomized, placebo-controlled, adaptive? What biomarkers are used for enrollment?
5. Endpoint patterns — what primary endpoints dominate and how do they compare across sponsors
6. Enrollment velocity — estimated enrollment rates and any signals of slow recruitment
7. Geographic concentration — where are sites located and what implications for patient access
8. Gaps and opportunities — phases or patient populations with no active programs

Format as an executive briefing with data tables and strategic commentary. Flag any trials with posted results or recent publications.

Compare these clinical trials side-by-side:

Trials to compare: [NCT ID 1], [NCT ID 2], [NCT ID 3 (optional)]
Disease area: [therapeutic area]

For each trial, extract and compare:
1. Sponsor and investigator
2. Phase and study design (randomized, blinded, controlled, adaptive)
3. Patient population — key inclusion/exclusion criteria
4. Intervention — drug, dose, schedule, and comparator arm
5. Primary and secondary endpoints
6. Target enrollment and current status
7. Number and location of sites
8. Regulatory designations (breakthrough, fast track, orphan)
9. Published results or interim data (if any)

Synthesize:
- Which trial design is most rigorous and why
- Which has the best chance of meeting its primary endpoint based on design quality
- Key differentiators between the programs
- Risks each program faces (enrollment, endpoint selection, competitive)

Present as a comparison table followed by strategic analysis.

Assess enrollment feasibility for a proposed clinical trial:

Trial design:
- Indication: [disease/condition]
- Phase: [1, 2, 3]
- Target enrollment: [number of patients]
- Key eligibility: [main inclusion/exclusion criteria]
- Duration: [planned enrollment period]
- Sites: [number and regions planned]

Analyze:
1. Disease prevalence and incidence in target geographies
2. How many patients meet the eligibility criteria (eligible pool estimate)
3. Competing trials recruiting from the same patient population
4. Historical enrollment rates for similar trials in this indication
5. Site selection considerations — academic vs. community, geographic spread
6. Patient burden assessment — visit frequency, procedures, duration
7. Diversity and representation considerations
8. Risk factors — seasonal patterns, referral pathways, standard-of-care competition

Provide enrollment projections with optimistic, base, and pessimistic scenarios. Recommend mitigation strategies for the top 3 enrollment risks.

Synthesize the clinical evidence for [drug/compound] in [indication]:

Compound: [name and mechanism of action]
Target: [biological target]
Indication: [disease/condition]
Development stage: [preclinical through approved]

Synthesize across all available evidence:
1. Preclinical data — in vitro potency, selectivity, animal models, PK/PD
2. Phase 1 results — safety, tolerability, PK, recommended Phase 2 dose
3. Phase 2 results — efficacy signals, dose-response, biomarker data
4. Phase 3 results — primary endpoint outcomes, key secondary endpoints
5. Safety profile — common AEs, serious AEs, discontinuation rates, class effects
6. Published literature — peer-reviewed publications, conference abstracts
7. Regulatory interactions — FDA feedback, special designations

Assess:
- Strength of efficacy evidence (strong, moderate, preliminary)
- Differentiation vs. standard of care
- Key uncertainties and data gaps
- Probability of regulatory success

Provide a structured evidence dossier with citations and confidence assessments.

Analyze safety signals for [drug name or drug class]:

Drug/class: [name]
Mechanism: [mechanism of action]
Indication(s): [disease areas]
Data sources to consider: [clinical trial data, FDA FAERS, published literature]

Analyze:
1. Adverse event profile from clinical trials — frequency, severity, relationship to dose
2. Serious adverse events and deaths — causality assessment
3. Post-marketing signals — FAERS data trends, new safety information
4. Class effects — are these signals expected based on the mechanism of action?
5. Comparison to competitor drugs — how does the safety profile compare?
6. Risk factors — patient subgroups at higher risk
7. Mitigation strategies — monitoring, dose modification, concomitant medications

Provide:
- Summary safety table with incidence rates
- Signal-to-noise assessment (true signal vs. reporting bias)
- Benefit-risk narrative for the target patient population
- Recommended label language and risk management plan elements

Evaluate regulatory pathway options for [drug candidate]:

Compound: [name]
Mechanism: [mechanism of action]
Indication: [disease/condition]
Current stage: [Phase of development]
Unmet medical need: [describe the gap in current treatment]

Assess pathway options:
1. Standard approval vs. accelerated pathways (breakthrough, fast track, priority review, accelerated approval)
2. Eligibility for each designation — what evidence supports it
3. Surrogate vs. clinical endpoints — which are acceptable and what's the precedent
4. Orphan drug designation eligibility and benefits
5. Pediatric requirements and timing
6. International strategy — EMA, PMDA alignment opportunities
7. Competitive regulatory context — what has been approved recently and how

Recommend:
- Optimal regulatory strategy with timeline
- Key regulatory risks and mitigation
- Recommended interactions with FDA (pre-IND, EOP2, pre-BLA/NDA)
- Evidence package needed for each milestone